International differences in epidemiology of lung adenocarcinoma

Charloux, Anne; Rossignol, Michel; Purohit, Ashok; Small, David; Wolkove, Norman; Pauli, G; Quoix, Élisabeth; Kreisman, Harvey

doi:10.1016/s0169-5002(96)00623-x

Cited by 42 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Moreover, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone predominantly induces adenocarcinoma in animal experiments. 46,47 Particularly in Japan, where room sizes tend to be small and living conditions congested, sidestream smoke may be directly transmitted to non-smoking women before dilution by room air. 10,45 As further support, our use of information from the husband himself likely enhanced the accuracy of exposure to passive smoking, owing to the low agreement between the husband's information on the duration or intensity of his smoking with that from the wife.…”

Section: Discussionmentioning

confidence: 99%

Passive smoking and lung cancer in Japanese non‐smoking women: A prospective study

Kurahashi

Inoue²,

Liu³

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Although smoking is a major cause of lung cancer, the proportion of lung cancer cases among Japanese women who never smoked is high. As the prevalence of smoking in Japan is relatively high in men but low in women, the development of lung cancer in nonsmoking Japanese women may be significantly impacted by passive smoking. We conducted a population-based prospective study established in 1990 for Cohort I and in 1993 for Cohort II. The study population was defined as all residents aged 40-69 years at the baseline survey. 28,414 lifelong non-smoking women provided baseline information on exposure to tobacco smoke from their husband, at the workplace and during childhood. Over 13 years of follow-up, 109 women were newly diagnosed with lung cancer, of whom 82 developed adenocarcinoma. Compared with women married to never smokers, hazard ratio (HR) [95% confidence interval (CI)] for all lung cancer incidence in women who lived with a smoking husband was 1.34 (95% CI 0.81-2.21). An association was clearly identified for adenocarcinoma (HR 2.03, 95% CI 1.07-3.86), for which dose-response relationships were seen for both the intensity (p for trend 5 0.02) and amount (p for trend 5 0.03) of the husband's smoking. Passive smoking at the workplace also increased the risk of lung cancer (HR 1.32, 95% CI 0.85-2.04). Moreover, a higher risk of adenocarcinoma was seen for combined husband and workplace exposure (HR 1.93, 95% CI 0.88-4.23). These findings confirm that passive smoking is a risk factor for lung cancer, especially for adenocarcinoma among Japanese women. ' 2007 Wiley-Liss, Inc.Key words: lung cancer; passive smoking; histological type; prospective study; Japanese non-smoking women In Japan, lung cancer has been the second leading cause of cancer death in women since the 1980s. 1 Although the majority of lung cancers can be attributed to cigarette smoking, 53% of all women with lung cancer world-wide are never smokers. 2,3 The proportion of Japanese female lung cancer patients who have never smoked is as high as 70%, 4 whereas the proportion of Japanese women aged 20 or more who smoke is only around 10%. 5 The major risk for lung cancer in Japanese women cannot therefore be attributed to smoking. Given that the urine of non-smokers exposed to passive smoking contains concentrations of carcinogenic N-nitroso compounds, which are specific to tobacco 6 and the smoking rate in Japanese men is high, at around 50%, 5 passive smoking might be an important risk factor for lung cancer in nonsmoking Japanese women.Since the publication of the first positive findings by Hirayama in Japan, many studies have investigated the relation between passive smoking and lung cancer in non-smoking women. 7 Recently, the International Agency for Research on Cancer (IARC) concluded that findings on the risk of lung cancer associated with environmental tobacco smoke were consistent. 8 Moreover, a meta-analysis of published studies estimated that the excess risk of lung cancer in non-smokers who lived with a smoker compared to those who live...

show abstract

Section: Discussionmentioning

confidence: 99%

Passive smoking and lung cancer in Japanese non‐smoking women: A prospective study

Kurahashi

Inoue²,

Liu³

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Among several types of lung carcinoma, a gradual increase in the incidence of adenocarcinoma has been recognized (15). However, the pathologic and biologic behavior of lung adenocarcinoma is not fully characterized, and the outcome of surgical treatment remains unsatisfactory, because approximately 35% of patients who have Stage I adenocarcinoma die as a result of spread of cancer within 5 years after resection (16).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Values of Stromal Proportion and PCNA, Ki-67, and p53 Proteins in Patients with Resected Adenocarcinoma of the Lung

et al. 2000

View full text Add to dashboard Cite

“…Nonsmall cell lung cancer (NSCLC), essentially consisting of adenocarcinoma, squamous cell carcinoma (epidermoid carcinoma) and large cell carcinoma, accounts for approximately 80% of all lung cancers (Travis et al, 1995). The incidence of pulmonary adenocarcinoma has been increasing and adenocarcinoma is now the most common histologic subtype in the US (Charloux et al, 1997;Landis et al, 1998).…”

mentioning

confidence: 99%

Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma

2003

View full text Add to dashboard Cite

Napsin A is an aspartic proteinase expressed in lung and kidney. We have reported that napsin A is expressed in type II pneumocytes and in adenocarcinomas of the lung. The expression of napsin was examined in 118 lung tissues including 16 metastases by in situ hybridisation. Napsin was expressed in the tumour cell compartment in 33 of 39 adenocarcinomas (84.6%), in two of 11 large cell carcinomas and in one lung metastasis of a renal cell carcinoma. Expression of napsin was found to be associated with a high degree of differentiation in adenocarcinoma. Immunohistochemistry was performed for three proteins currently used as markers for lung adenocarcinoma : surfactant protein-A, surfactant protein-B and thyroid transcription factor-1. Thyroid transcription factor-1 showed the same sensitivity (84.6%) as napsin for adenocarcinoma, whereas surfactant protein-A and surfactant protein-B showed lower sensitivities. Among these markers, napsin showed the highest specificity (94.3%) for adenocarcinoma in nonsmall cell lung carcinoma. We conclude that napsin is a promising marker for the diagnosis of primary lung adenocarcinoma. Lung cancer is the leading cause of cancer mortality in the world and one of the top incidence of cancers in Europe and the US (Black et al, 1997;Wingo et al, 1999). Lung cancer has a poor prognosis and even for patients with operable disease, the 5-year survival rate is 14% in the US (Landis et al, 1998). Nonsmall cell lung cancer (NSCLC), essentially consisting of adenocarcinoma, squamous cell carcinoma (epidermoid carcinoma) and large cell carcinoma, accounts for approximately 80% of all lung cancers (Travis et al, 1995). The incidence of pulmonary adenocarcinoma has been increasing and adenocarcinoma is now the most common histologic subtype in the US (Charloux et al, 1997;Landis et al, 1998).The lung is also a common site for metastases from tumours growing at other sites. From a clinical point of view, it is important to distinguish between primary lung adenocarcinoma and metastatic adenocarcinoma in the lung since treatment protocols differ depending on the origin. Primary lung adenocarcinoma develops from type II pneumocytes and from bronchiolar nonciliated secretory cells (Clara cells). Surfactant apoproteins, including surfactant protein-A (Sp-A) and surfactant protein-B (Sp-B) are used as markers for lung adenocarcinoma and thyroid transcription factor-1 (TTF-1) is used as a marker for lung adenocarcinoma, large cell carcinoma, small cell carcinoma and thyroid carcinoma (Kaufmann and Dietel, 2000b).Recently, a new aspartic proteinase, napsin A, was cloned and shown to be expressed in lung and kidney (Tatnell et al, 1998). Our group and another group have shown that napsin A is identical to the protein spots TAO1/TAO2 detected by two-dimensional gel electrophoresis of lung adenocarcinoma, and that napsin A is expressed in type II pneumocytes and lung adenocarcinomas (Chuman et al, 1999;Hirano et al, 2000). However, the detailed expression patterns of napsin A in association with other m...

show abstract

International differences in epidemiology of lung adenocarcinoma

Cited by 42 publications

References 13 publications

Passive smoking and lung cancer in Japanese non‐smoking women: A prospective study

Passive smoking and lung cancer in Japanese non‐smoking women: A prospective study

Prognostic Values of Stromal Proportion and PCNA, Ki-67, and p53 Proteins in Patients with Resected Adenocarcinoma of the Lung

Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma

Contact Info

Product

Resources

About